194 related articles for article (PubMed ID: 35332633)
41. Preclinical models of Waldenström's macroglobulinemia and drug resistance.
Ailawadhi S; Paulus A; Chanan-Khan A
Best Pract Res Clin Haematol; 2016 Jun; 29(2):169-178. PubMed ID: 27825463
[TBL] [Abstract][Full Text] [Related]
42. Tirabrutinib: First Approval.
Dhillon S
Drugs; 2020 Jun; 80(8):835-840. PubMed ID: 32382949
[TBL] [Abstract][Full Text] [Related]
43. Waldenström's macroglobulinemia.
Gertz MA; Fonseca R; Rajkumar SV
Oncologist; 2000; 5(1):63-7. PubMed ID: 10706651
[TBL] [Abstract][Full Text] [Related]
44. Waldenström's macroglobulinemia: treatment approaches for newly diagnosed and relapsed disease.
Hodge LS; Ansell SM
Transfus Apher Sci; 2013 Aug; 49(1):19-23. PubMed ID: 23773867
[TBL] [Abstract][Full Text] [Related]
45. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Gertz MA; Anagnostopoulos A; Anderson K; Branagan AR; Coleman M; Frankel SR; Giralt S; Levine T; Munshi N; Pestronk A; Rajkumar V; Treon SP
Semin Oncol; 2003 Apr; 30(2):121-6. PubMed ID: 12720120
[TBL] [Abstract][Full Text] [Related]
46. Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenström's macroglobulinaemia. Swiss Group for Clinical Cancer Research (SAKK).
Betticher DC; Hsu Schmitz SF; Ratschiller D; von Rohr A; Egger T; Pugin P; Stalder M; Hess U; Fey MF; Cerny T
Br J Haematol; 1997 Nov; 99(2):358-63. PubMed ID: 9375754
[TBL] [Abstract][Full Text] [Related]
47. [Clinical characteristics and prognosis of Waldenström's macroglobulinemia: a clinical data report from a single center].
Jia YC; Lu J; Qiang WT; Li L; Liu J; Jiang H; Fu WJ; Du J
Zhonghua Xue Ye Xue Za Zhi; 2020 Dec; 41(12):1020-1024. PubMed ID: 33445850
[No Abstract] [Full Text] [Related]
48. Efficacy and safety of therapeutic procedure for Waldenström's macroglobulinemia with hyperviscosity syndrome.
Ito K; Kawasaki T; Hirano K; Sekiguchi N
Ther Apher Dial; 2024 Jun; 28(3):417-423. PubMed ID: 38069574
[TBL] [Abstract][Full Text] [Related]
49. Bortezomib in relapsed or refractory Waldenström's macroglobulinemia.
Chen C; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):74-6. PubMed ID: 19362979
[TBL] [Abstract][Full Text] [Related]
50. Treatment of Waldenstrom's macroglobulinemia with nucleoside analogues.
Dimopoulos MA; O'Brien S; Kantarjian H; Estey EE; Keating MJ; Alexanian R
Leuk Lymphoma; 1993; 11 Suppl 2():105-8. PubMed ID: 7907250
[TBL] [Abstract][Full Text] [Related]
51. Spectral-domain optical coherence tomography of retinal vessels in Waldenström's macroglobulinemia.
Willerslev A; Larsen M; Rothenbuehler SP; Sørensen TL; Hammer T; Paques M; Munch IC
Acta Ophthalmol; 2020 Mar; 98(2):153-157. PubMed ID: 31423759
[TBL] [Abstract][Full Text] [Related]
52. A multicenter, open-label, uncontrolled, single-arm phase 2 study of tirabrutinib, an oral Bruton's tyrosine kinase inhibitor, in pemphigus.
Yamagami J; Ujiie H; Aoyama Y; Ishii N; Tateishi C; Ishiko A; Ichijima T; Hagihara S; Hashimoto K; Amagai M
J Dermatol Sci; 2021 Sep; 103(3):135-142. PubMed ID: 34376340
[TBL] [Abstract][Full Text] [Related]
53. IFN-alpha as induction and maintenance treatment of patients newly diagnosed with Waldenström's macroglobulinemia.
Vela-Ojeda J; García-Ruiz Esparza MA; Padilla-González Y; Rosas-Cabral A; García-Chávez J; Xolotl-Castillo M; Salazar-Exaire D; Arenas-Osuna J; Aviña-Zubieta JA; Vadillo-Buenfil M; Abraham-Majluf S
J Interferon Cytokine Res; 2002 Oct; 22(10):1013-6. PubMed ID: 12433280
[TBL] [Abstract][Full Text] [Related]
54. Fludarabine therapy in Waldenström's macroglobulinemia.
Dimopoulos MA; O'Brien S; Kantarjian H; Pierce S; Delasalle K; Barlogie B; Alexanian R; Keating MJ
Am J Med; 1993 Jul; 95(1):49-52. PubMed ID: 8328496
[TBL] [Abstract][Full Text] [Related]
55. Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia.
Treon SP; Hanzis C; Tripsas C; Ioakimidis L; Patterson CJ; Manning RJ; Sheehy P
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):133-5. PubMed ID: 21454214
[TBL] [Abstract][Full Text] [Related]
56. Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide.
Dimopoulos MA; Hamilos G; Efstathiou E; Siapkaras I; Matsouka C; Gika D; Grigoraki V; Papadimitriou C; Mitsibounas D; Anagnostopoulos N
Leuk Lymphoma; 2003 Jun; 44(6):993-6. PubMed ID: 12854900
[TBL] [Abstract][Full Text] [Related]
57. Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia.
Ghobrial IM; Witzig TE; Gertz M; LaPlant B; Hayman S; Camoriano J; Lacy M; Bergsagel PL; Chuma S; DeAngelo D; Treon SP
Am J Hematol; 2014 Mar; 89(3):237-42. PubMed ID: 24716234
[TBL] [Abstract][Full Text] [Related]
58. Advances in the treatment of Waldenström's macroglobulinemia.
Johnson SA
Expert Rev Anticancer Ther; 2006 Mar; 6(3):329-34. PubMed ID: 16503850
[TBL] [Abstract][Full Text] [Related]
59. The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström's Macroglobulinemia.
Ababneh O; Abushukair H; Qarqash A; Syaj S; Al Hadidi S
Clin Hematol Int; 2022 Jun; 4(1-2):21-29. PubMed ID: 35950210
[TBL] [Abstract][Full Text] [Related]
60. Extended rituximab therapy for previously untreated patients with Waldenström's macroglobulinemia.
Dimopoulos MA; Zervas C; Zomas A; Hamilos G; Gika D; Efstathiou E; Panayiotidis P; Vervessou E; Anagnostopoulos N; Christakis J
Clin Lymphoma; 2002 Dec; 3(3):163-6. PubMed ID: 12521393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
